Kristiansand S

• IVIGSeN Pending
  2022-501717-31-00 10 Idiopathic painful small fiber neuropathy or sensory neuronopathy.
• A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O … Pending
  2024-516327-14-00 4 Ovarian cancer
• Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET) Pending
  2025-521330-29-00 4 Major Depression Disorder (MDD)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW- … Recruiting
  2024-511346-39-00 3 2025-03-28 Immune-mediated necrotizing myopathy
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in par … Recruiting
  2024-513927-18-00 4 2026-02-16 Amyotrophic Lateral Sclerosis
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien … Recruiting
  2024-519059-28-00 5 2025-07-17 Chronic Heart Failure
• Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Tri … Recruiting
  2023-505573-32-00 5 2025-07-01 Immune Thrombocytopenia (ITP)
• The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr … Recruiting
  2024-517981-40-00 5 2025-06-06 Chronic Migraine
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 4 2025-03-27 Cancer
• Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl … Recruiting
  2023-506998-35-00 5 2025-01-08 Glioblastoma
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting
  2023-507692-21-00 3 2024-08-22 Bullous pemphigoid
• Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcuta … Recruiting
  2023-510184-35-00 6 2024-08-20 Rheumatoid arthritis
• The CORTAD study Recruiting
  2024-512888-31-00 11 2023-08-03 Primary adrenal insufficiency (PAI)
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting
  2024-510798-84-00 10 2022-01-28 Idiopathic sudden sensorineural hearing loss (ISSNHL)
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 4 2021-04-01 Cancer
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 5 2019-01-08 Prostate Cancer
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co

Showing 1–24 of 35 trials